Qicai Han

649 total citations
15 papers, 474 citations indexed

About

Qicai Han is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Qicai Han has authored 15 papers receiving a total of 474 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 9 papers in Cancer Research and 3 papers in Oncology. Recurrent topics in Qicai Han's work include Cancer-related molecular mechanisms research (7 papers), MicroRNA in disease regulation (6 papers) and RNA modifications and cancer (5 papers). Qicai Han is often cited by papers focused on Cancer-related molecular mechanisms research (7 papers), MicroRNA in disease regulation (6 papers) and RNA modifications and cancer (5 papers). Qicai Han collaborates with scholars based in China and United States. Qicai Han's co-authors include Songfeng Chen, Qing Tian, Juan Li, Ranran Sun, Guangying Cui, Xichun Cui, Xiaolong Chen, Jianhao Li, Yufan Gu and Zhigang Ren and has published in prestigious journals such as Bone, Cell Death and Disease and Oncotarget.

In The Last Decade

Qicai Han

15 papers receiving 473 citations

Peers

Qicai Han
Comparison fields: 5 of 55
  • Molecular Biology 378
  • Cancer Research 264
  • Pulmonary and Respiratory Medicine 74
  • Oncology 52
  • Surgery 32
Replace Sandra Lettlová with:
Sandra Lettlová Czechia
Yajie Zhao China
Kaitai Liu China
Lang Liu China
Pengshan Zhang China
Mahmoud Elguindy United States
Jindan Luo China
Jie Ju China
Wanfeng Zhang China
Sandra Lettlová Czechia View profile →
Citations per field, relative to Qicai Han
Qicai Han · 1×
Citations per year, relative to Qicai Han
Qicai Han · 1×

Countries citing papers authored by Qicai Han

Since Specialization
Citations

This map shows the geographic impact of Qicai Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qicai Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qicai Han more than expected).

Fields of papers citing papers by Qicai Han

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qicai Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qicai Han. The network helps show where Qicai Han may publish in the future.

Co-authorship network of co-authors of Qicai Han

This figure shows the co-authorship network connecting the top 25 collaborators of Qicai Han. A scholar is included among the top collaborators of Qicai Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qicai Han. Qicai Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
# Work Indexed citations
1 10
2 16
3 17
4 14
5 23
6 30
7 31
8 83
9 67
10 56
11
Upregulation of the long non-coding RNA FOXD2-AS1 is correlated with tumor progression and metastasis in papillary thyroid cancer.
21
12 21
13 64
14 15
15 6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026